NAUT

Nautilus Biotechnology, Inc.
CAPPED RATING

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Nautilus Biotechnology, Inc. (NAUT) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B+); its weakest is Value (F). The rating has held at C for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
F
Factor Score 0.1 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
B-
Factor Score 3.0 / 5.0
Momentum
B+
Factor Score 3.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.2
EV / EBITDA -3.9
Rev Growth YoY N/A
Gross Margin 90.8%
Price Return 3M 166.8%
Price Return 12M 43.4%
Catalyst Signal 0.00
Market Cap $303.1M
TTM Revenue $424.0K
Price / Sales 715.0
ROE -41.0%

Historical Factor Score Progression

Held C for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-13 F (0.1) C+ (2.5) B- (3.0) B+ (3.5) C+ (2.6) C (2.3)
2026-11-06 F (0.2) C+ (2.5) B- (3.0) B (3.2) C+ (2.7) C (2.3)
2026-10-30 F (0.0) C+ (2.5) C+ (2.8) C+ (2.8) C+ (2.7) C (2.2)
2026-10-23 F (0.0) C+ (2.5) C+ (2.8) C (2.2) C+ (2.6) C- (2.0)
2026-10-16 F (0.0) C+ (2.5) C+ (2.8) C- (1.9) C+ (2.6) C- (2.0)
Page 1 of 3